Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com

Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

By Jared Kaltwasser

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 2nd 2015

Rolapitant Gains FDA Approval for CINV

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

September 1st 2015

ASCO Publishes Policy Update on Genomic Testing for Cancer Susceptibility

Surabhi Dangi-Garimella, PhD

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

Mary Lou Smith on Ensuring Patients' Voices Are Heard

September 1st 2015

Mary Lou Smith on Ensuring Patients' Voices Are Heard

Sometimes patients are so concerned with being good patients that they simply agree to what the clinician has said without fully understanding, and it's important to ask questions and ensure their voices are heard, said Mary Lou Smith, MBA, co-founder of the Research Advocacy Network.

September 1st 2015

Elotuzumab Accepted for Priority Review by FDA for Previously-Treated Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.

August 31st 2015

Gene Signature Could Predict Development of Pancreatic Cancer, Allow Personalized Treatment

Surabhi Dangi-Garimella, PhD

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

August 31st 2015

ASCO Updates Guidelines for Advanced Lung Cancer

Surabhi Dangi-Garimella, PhD

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

August 31st 2015

New 340B Draft Guidance May Increase Bureaucracy

Surabhi Dangi-Garimella, PhD

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

August 30th 2015

Pharmacy Cost Trends Expected to Continue in the Double Digits

Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.

August 28th 2015

Protein Biomarker Can Predict Response to FOLFIRINOX in Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

August 28th 2015

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

August 27th 2015

Childhood Cancer Increases Risk of Recurrent Stroke

Surabhi Dangi-Garimella, PhD

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

August 27th 2015

A New Decision Support Tool for Surgical Oncology Launched

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

August 26th 2015

As Date for First Biosimilar to Hit the Market Draws Close, Reimbursement Remains Fuzzy

Surabhi Dangi-Garimella, PhD

The Biosimilars Council wants CMS to hold back on Medicare Part B reimbursement for biosimilars.

August 26th 2015

Do Survivorship Care Plans Improve PROs Among Cancer Patients?

Surabhi Dangi-Garimella, PhD

An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.

August 25th 2015

Colorectal Cancer Screening Gets Special Look in AJMC Papers

The deadly nature of colorectal cancer merited attention in the Affordable Care Act, which called for eliminating cost-sharing for screening to prevent deaths. The future of colorectal screening, its cost-effectiveness, and a possible way to limit unneeded tests are the topic of a recent series of papers in The American Journal of Managed Care.

August 25th 2015

Study Shows Promise for EHR-Based Algorithm in Reducing Cancer Diagnostic Delays

Surabhi Dangi-Garimella, PhD

A trigger built in patient EHRs can avoid follow-up delays in those at risk for developing certain types of cancers, a JCO study shows.

August 25th 2015

A Payer-Provider Collaboration to Add Value to Oncology Care

Surabhi Dangi-Garimella, PhD

Aetna and the University of Chicago Medicine kicked off a value-based oncology medical home model in July this year in an effort to transition from fee-for-service to value-based care.

August 24th 2015

Another Cancer Drug Pricing Tool, This Time From NCCN

Surabhi Dangi-Garimella, PhD

The National Comprehensive Cancer Network has announced the development of another "price" calculator that will help stakeholders assess the relative "value" of available options.

August 21st 2015

New Study Unravels Link Between Obesity and Breast Cancer

Surabhi Dangi-Garimella, PhD

The study published in Science Translational Medicine found that tissue stiffening in the breasts of obese women can drive the development of malignant disease.

Dr Veena Shankaran Encourages Patient-Physician Communication of Care Costs

August 20th 2015

Dr Veena Shankaran Encourages Patient-Physician Communication of Care Costs

There are many cost-related pieces in the grand picture of care that are devastating to families and patients, including copayments, hospital visit bills, transportation fees, and drug prices.

August 20th 2015

Phase 2 Basket Trial Results Claim Success in BRaf V600-Mutated Cancers

Surabhi Dangi-Garimella, PhD

Conducted by researchers at the Memorial Sloan Kettering Cancer Center, phase 2 results from a basket trial evaluated the efficacy of vemurafenib on nonmelanoma BRaf V600-mutated cancers in 122 patients across 23 global centers.

August 18th 2015

Pilot of Decision Support to Individualize Colorectal Cancer Screening Recommendations

Amy R. Schwartz, MD Forrest L. Levin, MS Joseph A. O'Neil, Jr, BS R. Scott Braithwaite, MD, MSc

Colorectal cancer screening involves balancing immediate harms with longer-term benefits; electronic medical record decision support may facilitate personalized benefit/harm assessment.

August 16th 2015

The Evolving Treatment Landscape and Innovative Payment Models in Oncology: An Expert Summit

This supplement summarizes proceedings from the AJMC Oncology Stakeholders Summit, Spring 2015 series, at which experts gathered to discuss the evolving treatment landscape in oncology and the development of innovative payment models to help reduce the cost of care without sacrificing quality of care.

August 16th 2015

Special Issue Looks at What's Ahead in Precision Medicine

New resources are being directed toward precision medicine, particularly in cancer care. With that in mind, Evidence-Based Oncology, a publication of The American Journal of Managed Care, devotes its current issue to articles and commentaries on this growing field.

August 14th 2015

Chemoprevention With Oral Contraceptives Could Be a Reality

Surabhi Dangi-Garimella, PhD

Evidence provided by a study published in The Lancet Oncology affirms that oral contraceptives provide long-term protection against endometrial cancer.

August 14th 2015

Gefitinib Approved as Frontline in EGFR-Positive NSCLC

Surabhi Dangi-Garimella, PhD

August 14th 2015

Need for Palliative Care for Improved Performance at the End of Life

Surabhi Dangi-Garimella, PhD

An article published in JAMA Oncology underscores the need for efforts to improve quality of life for cancer patients.

August 14th 2015

CHAARTED Study: Conceptual Shift in Early Prostate Cancer Treatment

Surabhi Dangi-Garimella, PhD

Analysis of results from the CHAARTED trial, published in the New England Journal of Medicine, has found that 6 cycles of chemotherapy (docetaxel) before androgen-deprivation therapy early in the treatment of metastatic prostate cancer significantly improved overall survival than treatment with ADT alone.

August 14th 2015

Sonidegib Approved for Basal Cell Carcinoma

Surabhi Dangi-Garimella, PhD

August 14th 2015

JAMA Oncology Study Validates Patient-Reported Outcomes

Surabhi Dangi-Garimella, PhD

A multicollaborative study conducted for the National Cancer Institute has resulted in a tool called the Common Terminology Criteria for Adverse Events (PRO-CTCAE). PRO-CTCAE can help integrate the patient perspective into adverse event reporting.

...

123 124 125 126 127 128 129 130 131

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions